Search
Selected Filter
Displaying 11–20 of 304 research results
-
SparingVision Recruiting for Clinical Trial of Cone-Preserving Gene Therapy for RP
Eye On the Cure Research NewsFirst cohort of patients has been dosed in Phase ½ clinical trial taking place in Pittsburgh and Paris
-
Atsena Doses First Patient in XLRS Gene Therapy Clinical Trial
Eye On the Cure Research NewsThe AAV.SPR gene delivery system used in the trial is designed to more safely reach targeted retinal cells
-
FDA Approves 8 MG Dosing of Eylea for Wet AMD, Diabetic Macular Edema, and Diabetic Retinopathy
Eye On the Cure Research NewsNew, higher treatment dose reduces frequency of eye injections for patients
-
IZERVAY Approved by FDA for Treatment of Geographic Atrophy Secondary to Advanced Dry AMD
Eye On the Cure Research NewsIn two Phase 3 clinical trials, IZERVAY slowed the growth rate of lesions, the regions of cell loss in the central retina, associated with geographic atrophy (GA)
-
Belite Bio Doses First Patient in Phase 3 Clinical Trial for Advanced Dry AMD (GA) Therapy
Eye On the Cure Research NewsThe company’s emerging, oral treatment is designed to slow vision loss
-
PYC Doses First Patient in Clinical Trial of RNA Therapy for RP11 (PRPF31 Mutations)
Eye On the Cure Research NewsThe emerging RNA therapy is designed to boost expression of the PRPF31 protein
-
Eye On the Cure Research News
The five-year grant will advance the emerging treatments toward clinical trials
-
Beacon Therapeutics to Advance XLRP, Cone-Rod Dystrophy, and Dry AMD Gene Therapies
Eye On the Cure Research NewsAn emerging XLRP gene therapy acquired from AGTC is the company’s lead clinical program
-
Coave Reports Encouraging Phase 1/2 Clinical Trial Results for PDE6B Gene Therapy
Eye On the Cure Research NewsThe company is expanding the trial to enroll younger patients with less advanced disease
-
Summary of the Eighth Annual Retinal Cell & Gene Therapy Innovation Summit 2023
Eye On the Cure Research NewsThe Retinal Cell and Gene Therapy Innovation Summit has emerged as one of the most essential events for researchers and companies developing treatments and cures for retinal degenerative diseases. In its eighth year, the Innovation Summit featured 30 presentations from retina experts from around the world with more than 300 people in attendance.
.png)
